DualityBio and Genentech Partner on Next-Gen ADCs
SHANGHAI, CHINA, Aug 28, 2026 Duality Biotherapeutics, Inc. (DualityBio) has entered into a global collaboration and license agreement with...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, CHINA, Aug 28, 2026 Duality Biotherapeutics, Inc. (DualityBio) has entered into a global collaboration and license agreement with...
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
